Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes

Medical Care

Volumn 47, Issue 1, 2009, Pages 61-68

  Clarke, Philip M ^a,b   Hayes, Alison J ^a,b   Glasziou, Paul G ^c   Scott, Russell ^d   Simes, John ^a,b   Keech, Anthony C ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Diabetes; EQ 5D; Mortality; Quality adjusted life years; Survival; Utility

Indexed keywords

FENOFIBRATE; PLACEBO;

ADULT; AGED; AMPUTATION; ARTICLE; AUSTRALIA AND NEW ZEALAND; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; HEALTH STATUS; HEART FAILURE; HUMAN; LEG ULCER; MAJOR CLINICAL STUDY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

AGED; ALGORITHMS; ANTILIPEMIC AGENTS; AUSTRALIA; CAUSE OF DEATH; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIFE TABLES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEW ZEALAND; OUTCOME ASSESSMENT (HEALTH CARE); PROCETOFEN; PROPORTIONAL HAZARDS MODELS; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; SURVIVAL ANALYSIS;

EID: 58449103548     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181844855     Document Type: Article

References (23)

1. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5:1-30.
2. Dolan P. Modeling valuations for Euroqol Health States. Med Care. 1997;35:1095-1108.
3. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med. 1990;9:1259-1276.
4. Park SM, Park MH, Won JH, et al. EuroQol and survival prediction in terminal cancer patients: a multi-center prospective study in hospice-palliative care units. Support Care Cancer. 2006;14:329-333.
5. Lenzen MJ, Scholte WMJ, op Reimer WJ, et al. The additional value of patient-reported health status in predicting 1-year mortality after invasive coronary procedures: a report from the Euro Heart Survey on Coronary Revascularisation. Heart. 2007;93:339-344.
6. FIELD Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovasc Dia-betol. 2004;3:9.
7. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-1861.
8. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
9. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci(Lond). 2001;101:671-679.
10. Clarke P, Gray A, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS) outcomes model (UKPDS 68). Diabetologia. 2004;47:1747-1759.
11. The Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care. 2007;30:1638-1646.
12. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337-343.
13. Brooks R, Rabin R, de Charro F, eds. The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective. Dordrecht, Netherlands: Kluwer Academic Publishers; 2003:299.
14. Szende A, Oppe M, Devlin N, eds. EQ-5D Value Sets: Inventory, Comparative Review and User Guide Series: EuroQol Group Monographs. Vol. 2. Springer; 2007:102.
15. Shaw JF, Johnson J, Coons SJ. US Valuation of the EQ-5D health states. Development and Testing of the Dl valuation model. Med Care. 2005; 43:203-220.
16. StataCorp. Statistical Software: Release 7.0. College Station, TX: Stata Corporation; 2001.
17. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
18. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69:239-241.
19. Glasziou P, Alexander J, Beller E, et al. Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial, Health and Quality of Life Outcomes. Health Qual Life Outcomes. 2007;5:21.
20. Schmittdiel J, Vijan S, Fireman B, et al. Predicted quality-adjusted life years as a composite measure of the clinical value of diabetes risk factor control. Med Care. 2007;45:315-321.
21. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271-292.
22. Feeny D, Furlong W, Saigal S, et al. Comparing directly measured standard gamble scores to HUI2 and HUI3 utility scores: group- and individual-level comparisons. Soc Sci Med. 2004;58:799-809.
23. Cobb FR, Kraus WE, Root M, et al. Assessing risk for coronary heart disease: beyond Framingham. Am Heart J. 2003;146:572-580.